Key Highlights

  • Net loss for the quarter ended September 30, 2026 was USD 32.0 million, or USD 0.40 per ordinary share, against USD 3.1 million, or USD 2.36, in the same quarter a year earlier.
  • Research and development expense rose to USD 25.5 million from USD 1.4 million, and general and administrative expense rose to USD 11.4 million from USD 1.7 million.
  • Cash, cash equivalents and marketable securities were USD 528.5 million on September 30, 2026, which management expects to fund operations into the second half of 2029.
  • A license agreement with Paragon signed on November 3, 2026 covers DMR-001 and DMR-002, with milestone payments of up to USD 22.0 million per licensed product.

A Clinical-Stage Cost Base Replaces a Tiny Prior-Year Loss

Damora Therapeutics (NASDAQ:DMRA) filed its Quarterly Report on November 4, 2026. The company is a clinical-stage biotech developing antibodies against mutant calreticulin, which drives blood disorders such as essential thrombocythemia and myelofibrosis. It has no product revenue. Operating expenses were USD 36.9 million, offset by other income of USD 4.9 million, mostly USD 4.2 million of interest on its cash and a USD 0.8 million gain on selling intellectual property. Nine-month net loss was USD 90.9 million, or USD 1.19 per share, against USD 9.1 million, or USD 6.88, so the prior-year comparison reflects a far smaller operation. Ordinary shares outstanding were 61,904,742 as of November 2, 2026.

Spending Detail and the Paragon License

The R&D increase of USD 24.1 million came from preclinical and clinical activity of USD 7.5 million, Manufacturing and control work of USD 7.5 million, personnel of USD 4.7 million and a USD 2.3 million Warrant obligation tied to Paramora, a Paragon affiliate. Of the quarter's R&D, USD 7.2 million related to services provided by Paragon. Under the license signed November 3, 2026, Damora owes a USD 2.5 million payment on first human dosing in a Phase 1 trial, plus tiered royalties described as low to mid single-digit rates on net sales of monospecific antibody products. The option on DMR-003 remains unexercised.

Funding Runway, Trial Timeline and Dilution Risk

Nine-month operating cash use was USD 59.7 million, and investing outflows included USD 179.5 million of marketable securities purchases. Financing included a February 2026 offering of 16,644,737 shares at USD 19.00, which raised about USD 295.5 million net, and an at-the-market program of up to USD 150.0 million, where selling shares over time can dilute holders. The Phase 1/1b CLARITY-101 trial of DMR-001 began in the quarter, with Australian approval and FDA clearance, and two proof-of-concept readouts are planned from mid-2027. A first regulatory submission for DMR-002 is planned for the fourth quarter of 2026. The company says it will still need more capital, and a failure to raise it could raise going-concern doubt.

Where Things Stand

The loss is large because Damora is building from almost nothing a year ago, not because of a one-off. Damora Therapeutics (NASDAQ:DMRA) lost USD 32.0 million in the quarter but holds USD 528.5 million, which it says funds operations into the second half of 2029. Next markers are the DMR-002 submission in the fourth quarter of 2026, preclinical data at the December 2026 hematology meeting, and the first proof-of-concept data from mid-2027.